Abstract
Different groups have described an impaired activity of the growth hormone (GH) / insulin-like growth factor I (IGF-I) axis in chronic heart failure (CHF) and its relation to poor clinical status and outcome. Nonetheless, the role for GH as potential therapeutic tool in HF is still controversial. NT-proBNP levels have been used to identify HF patients and correlate with both disease severity and prognosis. We sought to investigate the cardiovascular effects of GH treatment in patients with CHF due to ischemic heart disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
